Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
Feng WenHanrui ZhengPengfei ZhangJing ZhouHongdou ChenKexun ZhouQiu LiFeng BiPublished in: European journal of cancer care (2019)
mFOLFOX7 is a very high cost-effective alternative as the first-line treatment for those patients with advanced GC compared with mFOLFIRI.